Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with Imatinib mesylate for chronic or accelerated disease phase

Abstract

Kinetics of BCR-ABL transcript levels were determined in 19 patients with chronic myeloid leukemia (CML) treated with imatinib for chronic or accelerated phase. BCR-ABL transcript kinetics clearly characterize responses to imatinib and are highly predictive for disease progression.

This work underlines the importance of BCR-ABL transcript level monitoring.